A phase I dose-escalation trial of GD2-CAR T cells in children and young adults with diffuse midline gliomas to assess the feasibility of manufacturing, safety and tolerability, and to preliminarily assess efficacy.
- Robbie G. Majzner
- Sneha Ramakrishna
- Michelle Monje